62/100BBeiGene stock forecast 2026–2028What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for BeiGene is 418.00, 0.3% above the current price of 416.68. Their targets range from 367.00 to 470.00.
Of the 10 firms that rated BeiGene in the past 12 months, 10 rate it buy or strong buy, 0 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 367.00 to 470.00, with an average of 418.00.
| Buy | 10 | |
| Hold | 0 | |
| Sell | 0 |
12-month price target
| Highest target | 470.00 |
| Average target | 418.00 |
| Lowest target | 367.00 |
| Current price | 416.68 |
BeiGene price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their BeiGene price target and rating?
How analysts rate BeiGene, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
10 of 10 firms rate it buy now, against 9 of 9 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
BeiGene analyst upgrades, downgrades and price targets
The latest rating change came on 13 July 2026, when Jefferies upgraded BeiGene from Hold to Buy. Its price target is 380.00, from 420.00. The most recent new target came from Jefferies on 5 November 2026: 470.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 5 Nov 2026 | Jefferies Faisal Khurshid | — | 380.00 → 470.00 | +23.7% | 391.28 |
| 16 Oct 2026 | Morgan Stanley Sean Laaman | — | 395.00 → 425.00 | +7.6% | 368.08 |
| 8 Oct 2026 | RBC Capital | Reiterated · Outperform | 451.00 → 459.00 | +1.8% | 341.10 |
| 7 Oct 2026 | Truist Financial Gregory Renza | Reiterated · Buy | 416.00 → 420.00 | +1.0% | 365.21 |
| 10 Sept 2026 | Barclays | Reiterated · Overweight | 407.00 → 415.00 | +2.0% | 351.00 |
| 10 Aug 2026 | Wolfe Research Kalpit Patel | — | 340.00 → 370.00 | +8.8% | 358.38 |
| 6 Aug 2026 | Barclays | Reiterated · Overweight | 403.00 → 407.00 | +1.0% | 327.53 |
| 14 Jul 2026 | Barclays | Reiterated · Overweight | 409.00 → 403.00 | -1.5% | 303.96 |
| 13 Jul 2026 | Jefferies | Upgraded · Hold → Buy | 420.00 → 380.00 | -9.5% | 298.70 |
| 7 Jul 2026 | Truist Financial | Reiterated · Buy | 411.00 → 416.00 | +1.2% | 308.46 |
| 7 Jul 2026 | RBC Capital | Reiterated · Outperform | 436.00 → 451.00 | +3.4% | 309.46 |
| 2 Jun 2026 | RBC Capital Leonid Timashev | Reiterated · Outperform | 425.00 → 436.00 | +2.6% | 276.47 |
| 15 May 2026 | Leerink Partners | Reiterated · Outperform | 367.00 | — | 293.76 |
| 7 May 2026 | Morgan Stanley | — | 405.00 → 395.00 | -2.5% | 312.05 |
| 7 May 2026 | Guggenheim Michael Schmidt | Reiterated · Buy | 420.00 | — | 313.32 |
| 7 May 2026 | Barclays | Reiterated · Overweight | 394.00 → 409.00 | +3.8% | 313.32 |
| 4 May 2026 | Wells Fargo Yanan Zhu | — | 400.00 | — | 293.86 |
| 8 Apr 2026 | Truist Financial | — | 400.00 → 411.00 | +2.8% | 312.19 |
| 26 Mar 2026 | Wolfe Research Kalpit Patel | — | 340.00 | — | 276.95 |
| 16 Mar 2026 | Jefferies | Downgraded · Buy → Hold | — | — | — |
| 26 Feb 2026 | RBC Capital Leonid Timashev | — | 425.00 | — | 322.37 |
| 4 Feb 2026 | Barclays | Reiterated · Overweight | 385.00 → 394.00 | +2.3% | 346.38 |
| 12 Jan 2026 | Bernstein | — | 259.00 → 414.00 | +59.8% | 337.89 |
| 8 Jan 2026 | Morgan Stanley | — | 383.00 → 405.00 | +5.7% | 333.87 |
| 24 Nov 2025 | Truist Financial | — | 400.00 | — | 347.72 |
| 17 Nov 2025 | Jefferies | — | 420.00 | — | 376.63 |
BeiGene EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Revenue
EPS
Does BeiGene beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 89.1% off the result, either way, and their revenue estimate 6.3%, over the last 10 quarters.
- EPS beats
- 7 / 10
- Revenue beats
- 5 / 8
- Average EPS surprise, last 10What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +57.7%
- Since
- August 2024
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 5 Nov 2026 | 2.34 | 4.59 | +96.2% | 1.75B | 1.89B | +7.7% |
| Q2 FY2026 | 5 Aug 2026 | 1.63 | 2.05 | +25.8% | 1.62B | 1.71B | +4.9% |
| Q1 FY2026 | 6 May 2026 | 0.73 | 1.96 | +168.5% | 1.44B | 1.51B | +5.4% |
| Q4 FY2025 | 26 Feb 2026 | 1.60 | 0.58 | -63.7% | 1.47B | 1.50B | +2.2% |
| Q3 FY2025 | 6 Nov 2025 | 0.72 | 1.09 | +51.4% | 1.45B | 1.41B | -2.7% |
| Q2 FY2025 | 6 Aug 2025 | 0.48 | 0.84 | +75.0% | 1.44B | 1.32B | -8.8% |
| Q1 FY2025 | 7 May 2025 | -0.71 | 1.22 | +271.8% | 1.25B | 1.12B | -10.4% |
| Q4 FY2024 | 27 Feb 2025 | -0.88 | -1.43 | -62.5% | 1.04B | 1.13B | +8.5% |
| Q3 FY2024 | 12 Nov 2024 | -0.88 | -1.15 | -30.7% | — | 1.00B | — |
| Q2 FY2024 | 7 Aug 2024 | -2.10 | -1.15 | +45.2% | — | 929.17M | — |
BeiGene stock price 2026–2028: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
There are no price scenarios for BeiGene: its P/E has been above 60, or from losses, too often in the last five years to price its earnings at, and similar companies' P/Es put its value too far from its price to stand in. The earnings analysts expect are in the estimates above.
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.760 | 71.4258Price 35.76193 | +99.7% | |
| 29.080 | 56.2434Price 29.0896 | +93.4% | |
| 240.360 | 464.26205Price 240.36627 | +93.2% | |
| 202.040 | 384.58163Price 202.042,644 | +90.3% | |
| 161.340 | 305.52160Price 161.34396 | +89.4% | |
| 125.395 | 237.44178Price 125.40297 | +89.4% | |
| 159.580 | 300.48225Price 159.58376 | +88.3% |
Furthest below the fair value on each stock's page, updated every day.